Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Subscribe To Our Newsletter & Stay Updated
